PharmaTher Sponsors Research For Novel Delivery Of Ketamine
PharmaTher Inc (CSE: PHRM) this morning announced that it has entered into a sponsored research agreement. The agreement, which was
Read more
Pharmather
PharmaTher Collaborates For Research On Psychedelic Microdosing Tech
PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related to psychedelics. The company this
Read more
PharmaTher, Revive, Complete Psilocybin Intellectual Property Transaction
PharmaTher (CSE: PHRM) has seen the completion of the sale of its psilocybin program to that of Revive Therapeutics (CSE:
Read more
PharmaTher To Commence Phase 2 Clinical Study On Ketamine In Q2 2021
Pharmather Inc (CSE: PHRM) is successfully progressing on the development of its proposed phase 2 clinical study on ketamine in
Read more
PharmaTher Licenses Patented Microneedle Delivery Tech For Ketamine
PharmaTher Inc (CSE: PHRM) this morning announced that it has entered into an exclusive worldwide patent and know-how license agreement
Read more
PharmaTher Acquires Exclusive Rights To Patented Ketamine Formulation
PharmaTher Inc (CSE: PHRM) has entered into an exclusive worldwide license agreement for the development and commercialization of a patented
Read more
Revive Therapeutics Enters LOI To Acquire Psilocybin Program From PharmaTher
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a letter of intent to acquire PharmaTher Inc’s
Read more
PharmaTher Files Patent Application In US For Psilocybin Drug Combination To Treat Neurological Disorders
PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a provisional patent application with the US Patent and
Read more
FDA Grants PharmaTher Pre-IND Meeting For Treatment Of Parkinson’s With Ketamine
PharmaTher Inc (CSE: PHRM) this morning announced that the US Food and Drug Administration has granted the company a pre-investigational
Read more
PharmaTher Files With FDA For Pre-IND Meeting On Use Of Ketamine In Treatment Of Parkinson’s Disease
PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a pre-investigational new drug meeting request, as well as
Read more